Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA, or siRNA, in atherosclerotic cardiovascular disease, or ASCVD, patients with high lipoprotein(a) levels. These data were presented during the Late-Breaking Science Session of the American Heart Association, or AHA, Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association, or JAMA. “Results presented today showed that zerlasiran – 300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks – produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks. This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluates the effects of treatment over time, including intervals between doses. Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted and no safety concerns emerged with infrequent dosing,” the company stated. “Additional results from the ALPACAR-360 study continue to support the competitive profile of zerlasiran on key clinical endpoints assessing time-averaged reduction, maximum effect and tolerability. The Phase 2 data show zerlasiran has the potential to provide long term reductions in Lp(a) with infrequent dosing. We look forward to progressing zerlasiran into Phase 3 as a potentially promising new treatment for patients with high Lp(a),” said Curtis Rambaran, MD, Chief Medical Officer at Silence.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLN:
- Silence Therapeutics: Rising Assets Amid Growing Losses
- Silence Therapeutics Plc (SLN) Q3 Earnings Cheat Sheet
- Silence Therapeutics files automatic ordinary shares offering
- AstraZeneca deal has positive read for Silence Therapeutics, says Morgan Stanley
- AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
